Miller Anestesia

atipamezole in human volunteers. Br J Clin Phar-

macol 31:160–165, 1991.

528. Venn RM, Grounds RM: Comparison between dex-

medetomidine and propofol for sedation in the

intensive care unit: Patient and clinician percep-

tions. Br J Anaesth 87:684–690, 2001.

529. Triltsch AE, Welte M, von Homeyer P, et al: Bispec-

tral index-guided sedation with dexmedetomidine

in intensive care: a prospective, randomized, double

blind, placebo-controlled phase II study. Crit Care

Med 30:1007–1014, 2002.

530. Ely EW, Shintani A, Truman B, et al: Delirium as a

predictor of mortality in mechanically ventilated

patients in the intensive care unit. JAMA 291:1753–

1762, 2004.

531. Pandharipande PP, Pun BT, Herr DL, et al: Effect of

sedation with dexmedetomidine vs lorazepam on

acute brain dysfunction in mechanically ventilated

patients: The MENDS randomized controlled trial.

JAMA 298:2644–2653, 2007.

532. Baumgartner GR, Rowen RC: Transdermal cloni-

dine versus chlordiazepoxide in alcohol withdrawal:

A randomized, controlled clinical trial. South Med

J 84:312–321, 1991.

533. Baddigam K, Russo P, Russo J, Tobias JD: Dexme-

detomidine in the treatment of withdrawal syndro-

mes in cardiothoracic surgery patients. J Intensive

Care Med 20:118–123, 2005.

534. Siobal MS, Kallet RH, Kivett VA, Tang JF: Use of

dexmedetomidine to facilitate extubation in surgi-

cal intensive-care-unit patients who failed previous

weaning attempts following prolonged mechanical

ventilation: A pilot study. Respir Care 51:492–496,

2006.

535. Maze M, Angst MS: Dexmedetomidine and opioid

interactions: Defining the role of dexmedetomidine

for intensive care unit sedation. Anesthesiology

101:1059–1061, 2004.

536. Dasta JF, Kane-Gill SL, Durtschi AJ: Comparing

dexmedetomidine prescribing patterns and safety

in the naturalistic setting versus published data.

Ann Pharmacother 38:1130–1135, 2004.

537. Aantaa R, Kanto J, Scheinin M, et al: Dexmedeto-

midine, an alpha 2-adrenoceptor agonist, reduces

anesthetic requirements for patients undergoing

minor gynecologic surgery.Anesthesiology 73:230–

235, 1990.

538. Aho M, Lehtinen AM, Erkola O, et al: The effect

of intravenously administered dexmedetomidine

on perioperative hemodynamics and isoflurane

requirements in patients undergoing abdominal

hysterectomy. Anesthesiology 74:997–1002, 1991.

539. Koroglu A, Demirbilek S, Teksan H, et al: Sedative,

haemodynamic and respiratory effects of dexmede-

tomidine in children undergoing magnetic reso-

nance imaging examination: Preliminary results. Br

J Anaesth 94:821–824, 2005.

540. Koroglu A, Teksan H, Sagir O, et al: A comparison

of the sedative, hemodynamic, and respiratory

effects of dexmedetomidine and propofol in chil-

dren undergoing magnetic resonance imaging.

Anesth Analg 103:63–67, 2006.

541. Jaakola ML, Ali-Melkkila T, Kanto J, et al: Dexme-

detomidine reduces intraocular pressure, intuba-

tion responses and anaesthetic requirements in

patients undergoing ophthalmic surgery. Br J

Anaesth 68:570–575, 1992.

542. Scheinin B, Lindgren L, Randell T, et al: Dexmede-

tomidine attenuates sympathoadrenal responses to

tracheal intubation and reduces the need for thio-

pentone and peroperative fentanyl. Br J Anaesth

68:126–131, 1992.

543. Aho M, Erkola O, Kallio A, et al: Dexmedetomidine

infusion for maintenance of anesthesia in patients

undergoing abdominal hysterectomy. Anesth Analg

75:940–946, 1992.

544. Feld JM, HoffmanWE, Stechert MM, et al: Fentanyl

or dexmedetomidine combined with desflurane for

bariatric surgery. J Clin Anesth 18:24–28, 2006.

545. Bakhamees HS, El-Halafawy YM, El-Kerdawy HM,

et al: Effects of dexmedetomidine in morbidly obese

patients undergoing laparoscopic gastric bypass.

Middle East J Anesthesiol 19:537–551, 2007.

546. Dholakia C, Beverstein G, Garren M, et al: The

impact of perioperative dexmedetomidine infusion

on postoperative narcotic use and duration of stay

after laparoscopic bariatric surgery. J Gastrointest

Surg 11:1556–1559, 2007.

547. Talke P, Li J, Jain U, et al: Effects of perioperative

dexmedetomidine infusion in patients undergoing

vascular surgery.The Study of Perioperative Ischemia

Research Group. Anesthesiology 82:620–633, 1995.

548. Grant SA, Breslin DS, MacLeod DB, et al: Dexme-

detomidine infusion for sedation during fiberoptic

intubation: A report of three cases. J Clin Anesth

16:124–126, 2004.

549. Bekker AY, Kaufman B, Samir H, Doyle W: The use

of dexmedetomidine infusion for awake cranio-

tomy. Anesth Analg 92:1251–1253, 2001.

550. Bekker AY, Basile J, Gold M, et al: Dexmedetomi-

dine for awake carotid endarterectomy: efficacy,

hemodynamic profile, and side effects. J Neurosurg

Anesthesiol 16:126–135, 2004.

551. Hofer RE, Sprung J, Sarr MG,Wedel DJ: Anesthesia

for a patient with morbid obesity using dexmedeto-

midine without narcotics. Can J Anaesth 52:176–

180, 2005.

552. Janssen P: The pharmacology of haloperidol. Int J

Neuropsychiatry 3(Suppl 1)10, 1967.

553. DeCastro J, Mundeleer P: Anesthesie sans barbitu-

riques: la neuroleptanalgesie (R1407, R1625, hyder-

gine, procain). Anesth Analg 42:1022, 1959.

554. Scuderi PE: Droperidol: Many questions, few

answers. Anesthesiology 98:289–290, 2003.

555. Dershwitz M: Droperidol: Should the black box be

light gray? J Clin Anesth 14:598–603, 2002.

556. White PF: Droperidol:A cost-effective antiemetic for

over thirty years. Anesth Analg 95:789–790, 2002.

557. Gan TJ, Alexander R, Fennelly M, Rubin AP: Com-

parison of different methods of administering dro-

peridol in patient-controlled analgesia in the

prevention of postoperative nausea and vomiting.

Anesth Analg 80:81–85, 1995.

558. Gan TJ, White PF, Scuderi PE, et al: FDA «black

box» warning regarding use of droperidol for

postoperative nausea and vomiting: Is it justified?

Anesthesiology 97:287, 2002.

559. Bailey P, Norton R, Karan S: The FDA droperidol

warning: Is it justified? Anesthesiology 97:288–289,

2002.

560. Flood P, Coates KM: Droperidol inhibits GABA

and neuronal nicotinic receptor activation. Anes-

thesiology 96:987–993, 2002.

561. Borison H, Wang S: Physiology and pharmacology

of vomiting. Pharmacol Rev 5:193, 1953.

562. Janssen P: Zur Frage des Abbaus und der Ausschei-

dung der bei Neuroleptanalgesie zur Anwendung

kommenden Pharmaka.

Henschel W (ed): Die

Neuroleptanalgesie. Berlin, Springer-Verlag, 1966.

563. Fischler M, Bonnet F, Trang H, et al: The pharma-

cokinetics of droperidol in anesthetized patients.

Anesthesiology 64:486–489, 1986.

564. Michenfelder JD,Theye RA: Effects of fentanyl, dro-

peridol, and innovar on canine cerebral metabolism

and blood flow. Br J Anaesth 43:630–636, 1971.

565. Barker J, Harper A, McDowall D: Cerebral blood

flow, cerebrospinal fluid pressure and EEG activity

during neuroleptanalgesia induced with dehydro-

benzperidol and phenoperidine. Br J Anaesth

40:143, 1968.

566. Song D, Chung F,Yogendran S,Wong J: Evaluation of

postural stability after low-dose droperidol in outpa-

tients undergoing gynaecological dilatation and

curettage procedure. Br J Anaesth 88:819–823, 2002.

567. Prys-Roberts C, Kelman G: The influence of drugs

used in neuroleptanalgesia on cardiovascular and

ventilatory function. Br J Anaesth 39:134, 1967.

568. Corssen G, Domino E, Sweet R: Neuroleptanalgesia

and anesthesia. Anesth Analg 43:748, 1964.

569. Israel J, Jansen G, Dobkin A: Circulatory and respi-

ratory response to tilt with pentazocine (Win 20,

228), droperidol (R4749), droperidol-fentanyl

(Innovar),and methotrimeprazine in normal healthy

male subjects. Anesthesiology 26:253, 1965.

570. Wooltorton E: Droperidol: Cardiovascular toxicity

and deaths. Can Med Assoc J 166:932, 2002.

571. Yelonsky J, Katz R, Dietrich E: A study of some of

the pharmacologic actions of droperidol. Toxicol

Appl Pharmacol 6:37, 1964.

572. Birch AA, Boyce WH: Effects of droperidol-dopa-

mine interaction on renal blood flow in man.Anes-

thesiology 47:70–71, 1977.

573. Wetchler B, Collins I, Jacob L: Antiemetic effects of

droperidol on the ambulatory surgery patient.

Anesthesiol Rev 9:23, 1982.

574. Pandit SK, Kothary SP, Pandit UA, et al: Dose-

response study of droperidol and metoclopramide

as antiemetics for outpatient anesthesia. Anesth

Analg 68:798–802, 1989.

575. Hill RP, Lubarsky DA, Phillips-Bute B, et al: Cost-

effectiveness of prophylactic antiemetic therapy

with ondansetron, droperidol, or placebo. Anesthe-

siology 92:958–967, 2000.

576. Aldrete JA: Reduction of nausea and vomiting from

epidural opioids by adding droperidol to the infu-

sate in home-bound patients. J Pain Sympt Manage

10:544–547, 1995.

577. Kjellberg F, Tramer MR: Pharmacological control of

opioid-induced pruritus: A quantitative systematic

review of randomized trials. Eur J Anaesthesiol

18:346–357, 2001.

578. CressmanWA, Plostnieks J, Johnson PC: Absorption,

metabolism and excretion of droperidol by human

subjects following intramuscular and intravenous

administration. Anesthesiology 38:363–369, 1973.

579. DeRuiter G, Popescu D, DeBoer A: Pharmacokine-

tics of etomidate in surgical patients.Arch Int Phar-

macodyn Ther 249:180, 1981.

580. Breimer LT, Hennis PJ, Burm AG, et al: Pharmaco-

kinetics and EEG effects of flumazenil in volunteers.

Clin Pharmacokinet 20:491–496, 1991.

581. Moffet A: Clarke’s Isolation and Identification of

Drugs, 2nd ed. London, Pharmaceutical Press, 1986.

534

Farmacología y anestesia